搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
GEN
1 天
Weight Loss Drug Curbs Appetite, Burns Energy, Skips Side Effects
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Nature
5 年
Amylin's $1 billion heavyweight deal
Symlin is a synthetic version of amylin, a neuroendocrine hormone secreted by pancreatic beta cells, that boosts insulin action and helps regulate appetite, food intake and glucose control.
The Motley Fool
2 天
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Amylin is a hormone that helps regulate blood sugar levels and control appetite, while calcitonin is a metabolic hormone.
BioSpace
2 天
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
7 天
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
11 天
on MSN
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
来自MSN
4 天
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
While semaglutide works by hampering appetite and controlling blood sugar levels by mimicking the GLP-1 hormone, cagrilintide ...
Quartz on MSN
9 天
A new stronger Ozempic is coming. Here's what to know
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
11 天
Novo's new obesity drug, Wegovy in race to becoming top selling franchise
The first amylin drug was introduced to the market some 20 years ago ... The Danish drugmaker has already struggled to meet ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈